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The antimicrobial activity and 
biocompatibility of a controlled gentamicin- 
releasing single- layer sol- gel coating on 
hydroxyapatite- coated titanium
Aims
the aim of this study was to develop a single- layer hybrid organic- inorganic sol- gel coating 
that is capable of a controlled antibiotic release for cementless hydroxyapatite (hA)- coated 
titanium orthopaedic prostheses.
Methods
Coatings containing gentamicin at a concentration of 1.25% weight/volume (wt/vol), sim-
ilar to that found in commercially available antibiotic- loaded bone cement, were prepared 
and tested in the laboratory for: kinetics of antibiotic release; activity against planktonic 
and biofilm bacterial cultures; biocompatibility with cultured mammalian cells; and physi-
cal bonding to the material (n = 3 in all tests). the sol- gel coatings and controls were then 
tested in vivo in a small animal healing model (four materials tested; n = 6 per material), 
and applied to the surface of commercially pure hA- coated titanium rods.
results
the coating released gentamicin at > 10 × minimum inhibitory concentration (MIC) for sen-
sitive staphylococcal strains within one hour thereby potentially giving effective prophylax-
is for arthroplasty surgery, and showed > 99% elution of the antibiotic within the coating 
after 48 hours. there was total eradication of both planktonic bacteria and established 
bacterial biofilms of a panel of clinically relevant staphylococci. Mesenchymal stem cells 
adhered to the coated surfaces and differentiated towards osteoblasts, depositing calcium 
and expressing the bone marker protein, osteopontin. In the in vivo small animal bone 
healing model, the antibiotic sol- gel coated titanium (ti)/hA rod led to osseointegration 
equivalent to that of the conventional hA- coated surface.
Conclusion
In this study we report a new sol- gel technology that can release gentamicin from a 
bioceramic- coated cementless arthroplasty material. In vitro, local gentamicin levels are 
in excess of what can be achieved by antibiotic- loaded bone cement. In vivo, bone healing 
in an animal model is not impaired. This, thus, represents a biomaterial modification that 
may have the potential to protect at- risk patients from implant- related deep infection.
Cite this article: Bone Joint J 2021;103-B(3):522–529.
Introduction
The incidence of periprosthetic joint infection (PJI) 
is between 1% and 3% after primary arthroplasty 
and up to 15% after revision procedures.1,2 With 
the number of primary arthroplasties expected to 
increase to 1.26 million annually in the USA by 
2030, significantly more patients will be affected 
by infection in the future.3 The interface between 
the prosthesis 'foreign- body' and the patient’s 
tissues presents a particular challenge in the 
prevention of infection. While prophylactic anti-
biotics are used to reduce the risk of PJI during 
primary surgery, once an infection becomes 
established on the prosthesis, antibiotics alone 
will not cure a PJI. This is because a biofilm has 
now become established and the only solution is 
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radical surgery with appropriate antibiotic therapy. If, however, 
microorganisms entering the wound can be neutralized before 
a biofilm becomes established, the incidence of infection could 
be further reduced in both primary and revision surgery.
The local delivery of antibiotic provides higher concentra-
tions of antibiotic at the site of infection than can be achieved 
by systemic therapy. While this delivery can be provided using 
antibiotic- loaded bone cement, it can obviously only be used 
with cemented components. While there is now an established 
trend for the use of cementless components at both primary 
and revision surgery,2 local antibiotic delivery is not there-
fore available for cementless arthroplasty. In order to provide 
a local antibiotic delivery system for cementless compo-
nents, we developed a controlled- release antibiotic hybrid 
organic- inorganic sol- gel coating system for application onto a 
cementless implant material that is already coated with growth- 
promoting hydroxyapatite (HA).
Sol- gel systems are a group of materials which are prepared 
as a liquid sol that undergoes curing to produce a cross- linked 
matrix, which can be used as a coating. A range of these systems 
have been explored for biomedical applications, although there 
has been only one previous system tested as a drug- delivery 
coating for orthopaedic prostheses. This previous antibiotic- 
loaded sol- gel coating contained vancomycin and was tested 
on a titanium (Ti) alloy.4,5 It required a multilayer application 
and had limited opportunities for the tuning of its properties, 
since it only contained inorganic silica precursors. This study, 
using a rat Staphylococcus aureus osteomyelitis model, demon-
strated antimicrobial activity in vivo when vancomycin was in 
the sol- gel.5
We have developed a hybrid sol- gel process (Supplementary 
Figure a) to prepare thin silica- based films with controlled pore 
size, hydrophobicity, and toughness for delivery of an antibiotic 
from the surface of the implant. The broad- spectrum antibiotic, 
gentamicin, was used as the antimicrobial agent as it is the anti-
biotic which is most frequently used in bone cement today. It is 
active against both Gram- negative and Gram- positive bacteria, 
which are responsible for the majority of PJIs. The coating 
was developed to provide the release of gentamicin during the 
time taken to undertake a routine primary hip or knee arthro-
plasty, typically between one and two hours. Furthermore, it 
was predicted that a rapid antibiotic- releasing coating of a few 
micrometres in thickness would avoid long- term low levels of 
antibiotic elution. Such low levels have been observed with 
bone cement, and have been implicated in the development of 
resistant microorganisms during prolonged infections.6,7 We 
have added the growth factor, bone morphogenetic protein-2 
(BMP-2),8,9 to the coating to investigate any potential enhance-
ment of bone- healing properties.
Methods
Sol- gel coatings were prepared and cured at room temperature 
on 20 mm × 20 mm glass coverslips (for in vitro characteri-
zation) or HA- coated Ti cylinders (1 mm × 2 mm; for in vivo 
testing). Where stated, gentamicin and BMP-2 were incorpo-
rated into the coatings at 1.25% weight/volume (w/v) and 0.5 
µg ml-1 to 2 µg ml-1, respectively. Where necessary, bone cement 
containing 1.25% (w/v) of gentamicin was used as a control 
material. Elution kinetics of gentamicin and BMP-2 were moni-
tored analytically in vitro from coated glass samples. Antimi-
crobial activity of eluted gentamicin was confirmed against key 
pathogens in minimum inhibitory concentration (MIC) assays, 
as well as assays of biofilm formation and eradication. In vitro 
cytocompatibility testing and phenotypic assessment were 
performed using human mesenchymal stem cells (MSCs). In 
vivo biocompatibility analysis of the coatings on HA- coated Ti 
was performed in a rat healing model system. Full details of the 
methods can be found in the Supplementary Material, which 
also includes a completed ARRIVE checklist to show that we 
adhered to the ARRIVE guidelines.
statistical analysis. Statistical analyses were achieved us-
ing SPSS statistics software v23 (IBM, Armonk, New York, 
USA) and GraphPad Prism 6 software (GraphPad, San Diego, 
California, USA). For pull- out test analysis, the three coating 
types were compared using the Kruskal–Wallis test for non- 
parametric data. Statistical significance was set at p < 0.05.
results
Elution characteristics of the coating. The elution of gen-
tamicin from coated samples was compared with that from 
samples of commercial gentamicin- loaded bone cement 
containing 1.25% gentamicin (w/v, weight/weight (w/w), 
respectively) monitored over a 78- hour period. Elution was 
monitored into ammonium acetate buffer and into Dulbecco's 
Modified Eagle Medium (DMEM) cell culture medium (to 
mimic the mix of salts and other small molecules that are 
typically found in vivo). The mean gentamicin concentrations 
eluted from the sol- gel into the ammonium acetate buffer 
reached a maximum of 1.557 µg mm-2 (SD 0.296) after 48 
hours, representing > 99% of gentamicin contained within the 
coating. The mean amount of gentamicin eluted from bone 
cement reached a maximum of 0.775 µg mm-2 (SD 0.159) 
after 48 hours, representing only 4.98% of the original gen-
tamicin contained within the cement (Figure 1a). Similar data 
were obtained with elution into DMEM medium (Figure 1b). 
The coating with gentamicin achieved the MIC for key tar-
get organisms (staphylococci) within one hour, i.e. within the 
operating time for a typical arthroplasty. Unlike the bone ce-
ment system, complete elution of the gentamicin from within 
the coating was observed within 48 hours, removing the pos-
sibility of problematic longer- term elution.
Sol- gel preparations containing gentamicin (1.25% w/v) and 
BMP-2 (0.5 to 2 µg ml-1) were coated onto HA/Ti squares and 
eluted into DMEM cell culture media, and the eluted BMP-2 
concentration was measured by enzyme- linked immunosorbent 
assay (ELISA). After one week, concentrations ranged from 
180 pg ml-1 to 256 pg ml-1, corresponding to only 0.2% to 0.7% 
of the BMP-2 eluting from the coating (data not shown).
Antimicrobial properties of the gentamicin sol-gel coating. 
The gentamicin sol- gel coating was tested against a selection of 
clinical and laboratory strains of staphylococci. The antibiotic 
eluting from coated surfaces in a microtitre plate assay system 
gave a total kill of all clinical isolates and laboratory strains 
of Staphylococcus epidermidis and S. aureus within 24 hours 
(Figure 1c).
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Elution and antimicrobial properties of the gentamicin sol- gel coating: a) Elution of gentamicin per mm2 surface area against time and % gentamicin 
eluted for sol- gel and gentamicin- loaded bone cement (n = 3). The 100% elution corresponded to 3.3 mg to 3.6 mg of antibiotic for bone cement 
samples (1.25% weight/weight (w/w)) and 625 µg for sol- gel (1.25% weight/volume (w/v)) samples. b) Semi- log plot showing elution of antibiotic 
from gentamicin sol- gel (1.25% gentamicin w/v) coated hydroxyapatite/titanium (HA/Ti) squares into 0.1M ammonium acetate buffer and Dulbecco's 
Modified Eagle Medium (DMEM) cell culture media (n = 2). The minimum inhibitory concentration (MIC) breakpoint for Staphylococcus aureus 
and Staphylococcus epidermidis (1 µg mL-1) is shown as a dashed red line. c) Time- kill curve for sol- gel coating (1.25% gentamicin w/v) against 
staphylococcal laboratory strains and clinical isolates (CI) from infected prostheses (n = 3). d) Time- kill curve for sol- gel coating (1.25% gentamicin 
w/v) against established biofilms of staphylococcal laboratory strains and CI from infected prostheses (n = 3). All data are plotted as individual 
values from replicate experiments. Where no bacteria were recovered, +1 was added to zero CFU ml-1 values before log transformation of the data. 
MRSA, methicillin- resistant Staphylococcus aureus.
The gentamicin sol- gel coating was also tested against 
established biofilms from a selection of clinical and laboratory 
strains of staphylococci. Biofilms grown overnight on plastic 
pegs were submerged in fresh media, in wells of a 96- well plate 
containing the sol- gel coating. A total kill of the clinical isolate 
and laboratory strain of S. epidermidis and the laboratory strain 
S. aureus SH1000 was seen within 24 hours. The clinical isolate 
S. aureus strain showed a 3- log reduction between time 0 and 
24 hours, and a total kill after 72 hours (Figure 1d)
In vitro physical characterization of coating. The in vit-
ro adhesive properties of the sol- gel on HA- coated Ti, HA- 
Ti wire coated with sol- gel + gentamicin (1.25% w/v), and 
HA- Ti wire coated with sol- gel + gentamicin (1.25% w/v) 
+ BMP2 (2 µg ml-1) were assessed by a tensile pull- out test 
(Supplementary Figure b). All but two of nine samples that 
were tested snapped before pulling out of the bone cement 
(150 N to 220 N load). It should be noted that the cement 
into which the coated samples were embedded in these tests 
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Scanning electron microscopy (SEM) images of titanium/hydroxyapatite (Ti/HA) rods (1 mm × 2 mm) coated with sol- gel + gentamicin (1.25% 
weight/volume (w/v)) or sol- gel only showing: a) cut rod section prior to gamma (γ) irradiation; b) coated sol- gel + gentamicin surface showing 
crystals prior to γ irradiation; c) coated sol- gel + gentamicin surface after γ irradiation; d) coated sol- gel only surface prior to γ irradiation; e) coated 
sol- gel only surface after γ irradiation.
was antibiotic- free and used solely as a means to apply force 
to the outside of the coatings; there was no intention that the 
coatings should be embedded in cement during surgery. The 
samples that pulled out (~150 N) were not coated with sol- gel 
and failed at the interface between HA and Ti wire. There was 
no significant difference between the pull- out strengths of the 
samples (p = 0.875, Kruskal–Wallis test).
The preparation of coated rods for implantation in the small 
animal healing model required the cutting of 2 mm lengths from 
coated HA- Ti wire. These sections were then gamma (γ)- irra-
diated prior to in vivo implantation. Samples were examined 
by scanning electron microscopy (SEM) before and after γ-ir-
radiation to verify that the coating was still intact and that no 
delamination had occurred at the rod ends due to cutting. No 
delamination could be seen at the rod ends (Figure 2a), and 
crystals (gentamicin) could be seen on the gentamicin sol- gel 
coated surface (Figures 2b and c) and not on the sol- gel only 
coated rods (Figures 2d and e).
In vitro osteogenesis of mesenchymal stem cells in con-
tact with the coatings. Rat MSCs seeded onto glass cover-
slips coated with sol- gel adhered and spread onto the surface 
of all sol- gel surfaces, regardless of the agents which were in-
corporated. Clear filamentous actin staining was seen, demon-
strating cell spreading on the surface of sol- gel coated surfaces 
(Figure 3). Alizarin red staining demonstrated deposition of cal-
cium in all samples (Figure 3), consistent with differentiation of 
the MSCs into osteoblast- like cells. In contrast, MSCs cultured 
on uncoated coverslips did not display any calcium deposition 
(data not shown). MSCs cultured on coverslips coated with all 
sol- gel preparations expressed osteopontin (a protein marker of 
osteoblast differentiation) regardless of the agents which were 
incorporated (Figure 3).
In vivo osseointegration of implants coated with sol-gel. 
When the implants were tested in the rat healing model, no 
clinical signs of infection were observed on any implant and 
all were immobile, suggesting that osseointegration had oc-
curred. Micro- CT (µCT) analysis demonstrated that implants 
coated with sol- gel had comparable new bone volume to that 
of HA- coated Ti controls (Figure 4 and Supplementary Video 
1). No histological differences were seen between any of the 
test groups and each implant was seen to be surrounded by 
normal lamellar bone in close contact with the surface of the 
implant. The sol- gel coated implants did not show any histo-
logical differences from standard HA- coated Ti wire implants 
(Figure 5). Vital bone marrow was also seen in contact with 
the implant between areas of bone contact. In all cases, bone 
formation could be seen in the medullary cavity close to the 
implant and spanning the distance between the implant and the 
cortical bone, forming bone bridges. The new bone involved 
both lamellar bone and, in places, less organized woven bone. 
There was no evidence of fibrous encapsulation or inflamma-
tory response (Figure 5).
Discussion
These results show that sol- gel coating has suitable properties to 
provide controlled local gentamicin prophylaxis for cementless 
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Sol-gel + Gent Sol-gel + Gent + BMP-2
Fig. 3
Fluorescence microscopy images showing mesenchymal stem cells (MSCs) on sol- gel coating. MSCs were cultured on the surface of coated 
coverslips for four weeks. Phalloidin stain shows a filamentous actin component of MSCs in red. Alizarin red stains calcium deposits (associated 
with bone formation) red, and osteopontin (stained brown) is an MSC metabolite indicating differentiation. In contrast, cells cultured on coverslips 











































 Implant coating 
Fig. 4
Micro- CT (µCT) analysis of the percentage new bone formation 
normalized to tissue volume within the region of interest (ROI), defined 
as new bone formation in contact with the surface of the implant. Four 
implant coatings were investigated: hydroxyapatite (HA) alone; HA + 
sol- gel coating (HAsg); HA + sol- gel containing gentamicin (HAsgG); and 
HA + sol- gel coating containing gentamicin and bone morphogenetic 
protein-2 (BMP-2) (HAsgGB). Data plotted as individual values from 
three or four samples from each test group subjected to µCT analysis; 
medians are shown as horizontal lines.
orthopaedic prostheses, with bone healing properties that are 
comparable to an HA- coated surface currently in use. We found 
that the coating releases gentamicin in a controlled manner 
within a desirable time frame, with > 99% of the total antibi-
otic eluted within 48 hours. This time frame is compatible with 
effective prophylaxis during the peri- and postoperative period, 
to kill microorganisms resulting from surgical contamination 
and exclude the possibility of long- term elution.
When added, BMP-2 was retained within the coating and 
did not substantially elute. However, in vitro studies showed 
that BMP-2 was not required within the sol- gel coating to 
promote differentiation of MSCs, or required for effective in 
vivo bone healing.
Currently there are few options for local antibiotic delivery 
for cementless arthroplasty. A Defensive Antibacterial Coating 
(DAC) has been developed and trialled for use in hip and knee 
arthroplasties.10,11 This is a resorbable hydrogel, which can incor-
porate different antimicrobials and is applied by syringe during 
the operation. In vitro analysis of this coating has demonstrated 
elution of 99% after 96 hours of various antibiotics including 
vancomycin, gentamicin, and N- acetylcysteine. There was a 
reduction but not total eradication of S. aureus and S. epider-
midis established biofilms in vitro over a 48- hour period.12 
Clinical trials have shown that this system can reduce the rate 
of early surgical site infections and has not shown any adverse 
side effects.10,11 The physical nature of the hydrogel is somewhat 
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Typical sections of rat femur containing: a) hydroxyapatite- titanium (HA- Ti) implant (HA only); b) sol- gel + HA- Ti implant (HAsg); c) sol- gel + 
gentamicin (1.25% weight/volume (w/v)) + HA- Ti implant (HAsgG); d) sol- gel + gentamicin (1.25% w/v) + bone morphogenetic protein-2 (BMP-2) (2 
µg ml-1) HA- Ti implant (HAsgGB); and e) highlighted section of HAsgG showing bone bridge formation. Sections were stained using Stevenel’s blue 
and Van Gieson’s stains, with new bone stained pink. Images are examples from analysis of six animals in each group and were taken on an Apero 
CS2 scanscope (Leica Biosystems, Milton Keynes, UK, set at 40× magnification).
different from the sol- gel coating that has been developed in this 
study. The more physically robust and thinner sol- gel may be 
less likely to be removed from the surface during insertion into 
bone. The DAC system does, however, enable tailoring of local 
antibiotic delivery to individual patients who undergo a two- 
stage revision procedure, and in a recent case- controlled study 
the results with respect to the control of infection were better in 
the coated group.13 This is something we plan to evaluate in due 
course, along with a potential use of the coating in single- stage 
revision surgery for PJI. The high concentration of eluted local 
antibiotic may well be very efficacious in this surgical scenario, 
in which high concentrations of antibiotic are essential for the 
success of single- stage surgery for PJI.
A silver- based coating, Agluna, has been developed by 
Accentus Medical (Oxford, UK), and uses Ti nanotubes 
containing silver ions to provide an antimicrobial coating for 
metal implants. Retrospective analysis has shown that rates of 
infection were reduced using this technology, particularly in 
two- stage revision procedures where antibiotic- loaded cement 
was also used.14 A similar silver- based coating, Modular 
Universal Tumour And Revision System (MUTARS; Implant-
cast GmbH, Buxtehude, Germany) uses galvanic deposition to 
provide a coating of elemental silver.15 This technology reduced 
infection in a rabbit model. Clinical studies have also shown a 
reduction in infection rates compared with non- coated implants. 
In practice, these coatings have mainly been applied to tumour 
megaprostheses for use in major skeletal reconstruction and not 
for routine orthopaedic implants. A recent animal test model 
of a silver- containing HA coating found that it significantly 
reduced the burden of methicillin- resistant Staphylococcus 
aureus (MRSA) infection, and that this effect was enhanced by 
introducing a vancomycin solution at the surgical site.16 A ques-
tion still remains about the cytotoxicity of silver- based prod-
ucts, particularly long term.17
Synthes GmbH (Oberdorf, Switzerland) produce the Expert 
tibial nail PROtect, a tibial nail with a gentamicin coating that 
has shown promising results in preventing surgical site infec-
tions. This system uses a biodegradable polylactic acid coating 
for the release of gentamicin to provide antibiotic prophy-
laxis. Elution of 75% of gentamicin from the coating over 42 
days was demonstrated in vitro, with a significant reduction 
in adhesion of S. aureus over 24 hours. In vivo elution studies 
showed similar results, although trace levels of gentamicin 
were detected after six weeks.18 However, this application is 
currently limited to the surgical treatment of tibial fractures and 
the technology has not been expanded for use with arthroplas-
ties.19 A gentamicin- loaded ultra- high molecular weight poly-
ethylene material enables local delivery of antibiotic, although 
its use is limited to spacers used in two- stage revision surgery.20
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The sol- gels which have previously been shown to have 
potential as controlled release antimicrobial coatings used 
vancomycin, which provides no protection against infection 
caused by Gram- negative organisms.4,5 The single- layer hybrid 
sol- gel technology described in this paper targets a wider range 
of Gram- positive and Gram- negative organisms by using 
gentamicin. It is easy to apply and has the potential to adjust 
its hydrophobicity for elution of a wide range of therapeutic 
molecules, including antibiotics. Moreover, its antimicrobial 
and biocompatibility properties were demonstrated when it 
was applied to HA- coated implant material of the type widely 
used for promoting bone growth on uncemented prostheses. 
In vivo bone attachment was shown to be comparable to the 
HA- coated Ti surface of a type currently used in orthopaedic 
prostheses. In future, we propose to investigate the suitability 
of the coating for delivering a wide range of antibacterial and 
antifungal drugs, including combinations of antimicrobials, 
and application of the coating onto a range of materials used 
in orthopaedic surgery. We also propose to investigate a range 
of antibiotic loading levels and perform further in vivo testing, 
in particular to establish whether the coating can be modified 
quickly to kill biofilms as well as planktonic bacteria. In this 
way, it may be possible to design coatings which can protect 
against a wider range of organisms, facilitating a stratified or 
patient- specific approach.
take home message
  - There is a need for new systems to provide local 
antimicrobial prophylaxis for uncemented orthopaedic 
prostheses.
  - Here we report a single- layer gentamicin- containing hybrid organic- 
inorganic coating capable of controlled release of active antibiotic.
  - The coating is fully biocompatible with bone healing in a small animal 
in vivo system, suggesting promise for development as a coating for 
orthopaedic implants.
twitter
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supplementary material
  Includes the ARRIVE checklist and detailed methods 
of coating preparation, in vitro testing, and the small 
animal bone healing in vivo model study. Figure a 
shows the molecular structure of the sol- gel coating matrix. 
Figure b shows pull- out testing to assess the strength of adhe-
sion of the coating to orthopaedic implant material. Video 1 
shows animated 3D image from micro- CT (µCT) analysis of a 
transverse section of a rat femur implanted with a gentamicin 
sol- gel coated titanium rod, at the end of the healing trial. Bone 
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